02.13.07
Caroline Satyadi has joined SRI International as manager of operations for Quality Clinical Labs (QCL) in Mountain View, CA. QCL was acquired by SRI in April 2006, and performs clinical pathology analyses in compliance with GLP regulations. QCL specializes in clinical hematology and chemistry evaluations, which are a key component of the preclinical safety studies required by the FDA in the development of new drugs.
Ms. Satyadi will be responsible for the day-to-day operations of the lab, including supervision of all staff, technical oversight, liaison with clients, and interfacing with SRI's QA unit to assure compliance. Prior to joining SRI, Ms. Satyadi served as director of lab services at Colusa Regional Medical Center in Colusa, CA. She has also served as manager of laboratories at IMPATH, NAMSA, and MDS Diagnostic Labs and as a research biostatistician for USC School of Medicine.
"We are very pleased that Caroline has joined the QCL team at SRI," said Jon Mirsalis, Ph.D., D.A.B.T., managing director of SRI International's Biosciences Division. "Her impressive credentials and nearly 20 years of experience managing clinical laboratories will be a strong asset as we provide SRI clients and partners with the safety studies required to move drugs closer to the clinic and the marketplace."
Ms. Satyadi will be responsible for the day-to-day operations of the lab, including supervision of all staff, technical oversight, liaison with clients, and interfacing with SRI's QA unit to assure compliance. Prior to joining SRI, Ms. Satyadi served as director of lab services at Colusa Regional Medical Center in Colusa, CA. She has also served as manager of laboratories at IMPATH, NAMSA, and MDS Diagnostic Labs and as a research biostatistician for USC School of Medicine.
"We are very pleased that Caroline has joined the QCL team at SRI," said Jon Mirsalis, Ph.D., D.A.B.T., managing director of SRI International's Biosciences Division. "Her impressive credentials and nearly 20 years of experience managing clinical laboratories will be a strong asset as we provide SRI clients and partners with the safety studies required to move drugs closer to the clinic and the marketplace."